Groupe la Francaise Has $2.12 Million Stock Holdings in Abbott Laboratories $ABT

Groupe la Francaise grew its position in shares of Abbott Laboratories (NYSE:ABT) by 121.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,494 shares of the healthcare product maker’s stock after acquiring an additional 8,482 shares during the quarter. Groupe la Francaise’s holdings in Abbott Laboratories were worth $2,118,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Costello Asset Management INC bought a new position in Abbott Laboratories in the first quarter valued at approximately $136,000. Bouchey Financial Group Ltd acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $203,000. Intrust Bank NA raised its stake in shares of Abbott Laboratories by 1.9% during the 1st quarter. Intrust Bank NA now owns 21,846 shares of the healthcare product maker’s stock worth $2,898,000 after purchasing an additional 416 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Abbott Laboratories by 29.2% in the first quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker’s stock valued at $2,120,516,000 after buying an additional 3,616,471 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.9%

Shares of NYSE:ABT opened at $125.23 on Thursday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The business has a 50 day moving average of $128.87 and a 200-day moving average of $130.94. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market cap of $217.75 billion, a PE ratio of 15.69, a P/E/G ratio of 2.33 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. During the same period last year, the firm posted $1.21 EPS. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were paid a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Analysts Set New Price Targets

A number of brokerages have commented on ABT. Benchmark began coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price target for the company. Barclays raised their target price on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research note on Friday, October 17th. Evercore ISI lowered their price target on Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Sanford C. Bernstein raised their price objective on Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Finally, Raymond James Financial boosted their target price on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.